# A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

> **NCT03253471** · PHASE1 · TERMINATED · sponsor: **Alios Biopharma Inc.** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** AL-611
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03253471
- **Lead sponsor:** Alios Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-07
- **Primary completion:** 2017-09-18
- **Final completion:** 2017-09-18
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Strategic decision to discontinue further development of investigational compounds for the treatment of hepatitis C.
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03253471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03253471, "A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03253471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*